Washington, DC, primary headquarters in London, U.K.; probably the world’s largest privately-held biotechnology company in the late 1980s; biopharmaceutical productsand biodefense R&D contracting were acquired by Beaufour Ipsen S.A. in 1994; Porton along with DynCorp, Computer Sciences Corp. (CSC), was formerly part of the DynPort biodefense joint venture; Porton’s/Beaufour Ipsen’s 49% interest in DynPort was acquired by CSC in Aug. 2004.
